lineage

Y-27632 dihydrochloride (Y-27632 2HCl) is an orally potent, ATP-competitive inhibitor of ROCK-I and ROCK-II. Y-27632 dihydrochloride also inhibits isolation-induced apoptosis in mouse prostate stem or progenitor cells.

GW806742X is an inhibitor of Mixed Lineage Kinase Domain-Like protein (MLKL) which binds the MLKL pseudokinase domain (Kd: 9.3 μM) with anti-necroptosis activity. GW806742X has activity against VEGFR2.

URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and also inhibits LRRK2 activity (IC50: 11 nM).

Necrosulfonamide ((E)-Necrosulfonamide) is a necroptosis inhibitor that targets MLKL and is selective. Necrosulfonamide prevents the MLKL-RIP1-RIP3 necrosomal complex from interacting with its downstream effectors.

Menin-MLL inhibitor 20 is an irreversible inhibitor of the menin-MLL interaction, exhibiting antitumor activities.

NUC-7738 is a 5'-aryloxyphosphoamidate prodrug of 3'-dA that reduces β-catenin nuclear expression in AML cells, modulates β-catenin signaling, and can be used in cancer research.

L-Pyrrolysine is a specialized amino acid that resides in the archaeal lineage and responds to the amber (TAG) codon found in a few archaea and bacteria.

Cbl-b-IN-3 is a potent inhibitor of casitas b lineage lymphoma proto-oncogene-b (Cbl-b) (ic50 < 1 nM).

Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active small-molecule, nonpeptide thrombopoietin receptor agonist that stimulates megakaryopoiesis. It binds to and activates the transmembrane domain of the platelet thrombopoietin receptor (TPO-R or CD110), promoting the proliferation and differentiation of megakaryocytic cells and enhancing platelet production.

TC-5115 is a highly potent, selective inhibitor of the SET domain of the histone lysine methyltransferase MLL1 (KMT2A), with an IC₅₀ value of 16 nM. TC-5115 exhibits weak inhibitory activity against other methyltransferases such as SET7/9, DOT1L, and EZH2 (IC₅₀ > 1 μM). TC-5115 induces differentiation and growth arrest in leukemia cells and can be used in leukemia research.

M-89, a highly potent and specific inhibitor of the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction, exhibits a Kd of 1.4 nM for menin binding. This compound holds potential for treating MLL leukemia.

Menin-MLL inhibitor 4 has antitumor activity.Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction .

MM-589 is a potent WD repeat domain 5 (WDR5) inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.

MM-589 TFA is a potent inhibitor of WD repeat domain 5 (WDR5) and a modulator of mixed lineage leukemia (MLL) protein-protein interaction.

TC13172 is a potent and covalent inhibitor that specifically targets the mixed lineage kinase domain-like protein (MLKL), exhibiting significant selectivity for MLKL over the closely related receptor-interacting serine/threonine kinase 1 (RIPK1) and RIPK3 at a concentration of 10 µM.TC13172 effectively inhibits necroptosis induced by the TSZ combination (TNF-α, a Smac mimetic, and Z-VAD-FMK) in HT-29 cells with a EC50 of 2 nM and, at 100 nM, blocks TSZ-induced oligomerization and plasma membrane translocation of MLKL.

Enzomenib is a menin protein inhibitor that disrupts the interaction between menin and mixed lineage leukemia fusion proteins, thereby modulating transcriptional programs driven by MEN gene dysregulation and providing a targeted research tool for mechanistic studies and therapeutic exploration in hematological malignancies associated with menin-dependent oncogenic signaling.

PROTAC MLKL Degrader-2, a PROTAC that targets MLKL (Mixed Lineage Kinase), incorporates the PROTAC target protein ligand, E3 ligase ligand Thalidomide, and PROTAC Linker N-Methylpiperazine. The conjugate of the E3 ubiquitin ligase ligand and Linker is Thalidomide-N-Methylpiperazine. This compound exhibits antinecroptotic activity in human cell lines and effectively degrades MLKL in the HT-29 xenograft mouse model.

MLK3-IN-1 (Compound 37) is a selective inhibitor of mixed-lineage kinase 3 (MLK3) with an IC50 of less than 1 nM. It also inhibits FAK with an IC50 of 15.5 μM. In both murine and human liver microsomes, MLK3-IN-1 demonstrates excellent metabolic stability.

Cbl-b-IN-15 (compound 25) is an inhibitor of the RING finger E3 ubiquitin ligase Cbl, demonstrating an IC50 of 15 nM. Cbl-b refers to Casitas B-lineage Lymphoma proto-oncogene-b, which can inhibit the activation of T cells, natural killer (NK) cells, and B cells. Cbl-b-IN-15 can activate T cell function with an EC50 of 0.41 μM.

Cbl-b-IN-20 (Example 50) is an inhibitor of casitas B-lineage lymphoma proto-oncogene-b (Cbl-b), with an IC50 value of less than 100 nM.

Z116334910 is a competitive WDR5-MLL1 interaction disruptor, where WDR5 (WD Repeat-containing protein 5) is crucial for the methyltransferase activity of the MLL1 (mixed lineage leukemia 1) complex, and can be used for cancer research.

RIPK1-IN-34 is a selective RIPK1 inhibitor capable of penetrating the blood-brain barrier with an IC50 of 126.70 nM, showing minimal inhibition of RIPK3 (IC50 > 10,000 nM). It exerts significant neuroprotective effects by inhibiting the phosphorylation of RIPK1, RIPK3, and mixed lineage kinase domain-like pseudokinase (MLKL) in the necroptosis pathway. RIPK1-IN-34 demonstrates neuroprotective effects in rat models of middle cerebral artery occlusion (MCAO) and is a candidate for research in the treatment of acute ischemic stroke (AIS).

Cbl-b-IN-30 is an orally active inhibitor of Casitas B-lineage lymphoma-b (CBLB). It specifically binds to CBLB and inhibits its E3 ubiquitin ligase activity, with an IC50 value of 9.1 nM. Cbl-b-IN-30 promotes IL-2 secretion (EC50 value of 187.5 nM) and enhances T cell activation. This compound also exhibits antitumor activity and can induce immune memory. It is useful for colon cancer research.

MIV-6 is an inhibitor of the menin-mixed lineage leukemia interaction.